Monopar Therapeutics 8-K

What Happened Monopar Therapeutics, Inc. filed an 8-K reporting the results of its Annual Meeting held June 22, 2026. As of the April 27, 2026 record date, 6,698,778 shares were entitled to vote and 5,760,392 shares were represented at the meeting. Stockholders elected six directors, approved the named executive officers' compensation on an advisory (non‑binding) basis, approved the Company’s 2026 Stock Incentive Plan, and ratified the selection of BPM LLP as the independent registered public accounting firm for 2026.

Key Details

• Shares: 6,698,778 shares entitled to vote; 5,760,392 shares represented at the meeting (quorum).
• Director elections (For / Withheld / Broker non-votes = 799,255):
  • Christopher M. Starr, Ph.D.: 4,203,485 For; 757,652 Withheld
  • Chandler D. Robinson, MD MBA MSc: 4,447,108 For; 514,029 Withheld
  • Raymond W. Anderson, MBA MS: 4,671,362 For; 289,775 Withheld
  • Kim R. Tsuchimoto: 4,325,379 For; 635,758 Withheld
  • Lavina Talukdar, CFA: 4,897,733 For; 63,404 Withheld
  • Nicole Sweeny: 4,911,758 For; 49,379 Withheld
• Advisory say-on-pay vote: 4,355,628 For; 604,858 Against; 651 Abstain; 799,255 Broker non-votes (approved).
• 2026 Stock Incentive Plan: 4,444,209 For; 516,570 Against; 358 Abstain; 799,255 Broker non-votes (approved).
• Auditor ratification: BPM LLP ratified — 5,759,198 For; 998 Against; 196 Abstain.

Why It Matters These outcomes confirm the company’s governance slate and give stockholder approval (including for equity compensation) needed to implement the 2026 Stock Incentive Plan, which may affect future equity awards and potential dilution. The advisory approval of executive compensation signals stockholder support but is non‑binding. Ratifying BPM LLP maintains continuity for the company’s independent audit oversight for 2026.